CLDI Company Profile and Key Details

AMEX : CLDI

Calidi Biotherapeutics

$0.24

0.0115+5.09%

At Close 4:00 PM

$0.27

0.2375+13.18%

Pre-Market 08:30 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Calidi Biotherapeutics, Inc. (CLDI) stock surged +5.09%, trading at $0.24 on AMEX, up from the previous close of $0.23. The stock opened at $0.22, fluctuating between $0.22 and $0.24 in the recent session.

Stock Snapshot

0.226

Prev. Close

1.75M

Market Cap

0.2227

Day Low

-0.04

P/E Ratio

-5.95

EPS (TTM)

N/A

Cash Flow per Share

0.22

Open

7.37M

Number of Shares

0.2434

Day High

93.64%

Free Float in %

N/A

Book Value

2.73M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 27, 2026	0.22	0.24	0.22	0.24	2.79M
Apr 23, 2026	0.23	0.23	0.21	0.22	1.91M
Apr 22, 2026	0.24	0.24	0.22	0.23	2.86M
Apr 21, 2026	0.25	0.29	0.21	0.22	12.44M
Apr 20, 2026	0.27	0.27	0.24	0.25	1.68M
Apr 17, 2026	0.28	0.28	0.27	0.28	1.08M
Apr 16, 2026	0.27	0.28	0.26	0.28	3.28M
Apr 14, 2026	0.28	0.28	0.26	0.27	1.93M
Apr 13, 2026	0.25	0.30	0.25	0.28	2.93M
Apr 10, 2026	0.26	0.26	0.25	0.26	466.67K
Apr 09, 2026	0.26	0.27	0.25	0.26	765.65K
Apr 08, 2026	0.25	0.26	0.21	0.25	691.42K
Apr 07, 2026	0.25	0.25	0.23	0.24	390.03K
Apr 06, 2026	0.24	0.25	0.23	0.24	391.95K
Apr 02, 2026	0.24	0.25	0.23	0.24	285.91K
Apr 01, 2026	0.24	0.25	0.24	0.24	158.67K
Mar 31, 2026	0.23	0.24	0.21	0.24	558.66K
Mar 30, 2026	0.29	0.29	0.21	0.24	834.28K
Mar 27, 2026	0.27	0.28	0.26	0.27	237.3K
Mar 25, 2026	0.29	0.29	0.28	0.29	198.61K

Contact Details

San Diego, CA 92121

United States

https://calidibio.com 858 794 9600

About Company

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.

Stock Peers

TBXU

-0.559-1.85%

Direxion Daily Biotech Top 5 Bull 2X ETF$29.71 PTHS

1.71+7.42%

Pelthos Therapeutics Inc.$24.77 PTN

-0.72-3.24%

Palatin Technologies, Inc.$21.50 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 ARMP

-1.92-14.86%

Armata Pharmaceuticals, Inc.$11.00 CYBN

0.1+1.22%

Cybin Inc.$8.28 NRXS

0.27+3.44%

NeurAxis, Inc.$8.13 CVM

0.06+1.88%

CEL-SCI Corporation$3.26 NSRX

-0.42-11.67%

Nasus Pharma Ltd.$3.18 CANF

0.01+0.34%

Can-Fite BioPharma Ltd.$2.92

Company Overview

Calidi Biotherapeutics, Inc. (AMEX:CLDI) closed at $0.24 USD, gaining $0.01 (5.09%) from the previous close of $0.23. The stock is currently mid-range between its 52-week high and low $0.21 and $19.20. With a market capitalization of about $1.75 million, Calidi Biotherapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.42). Key stats such as the average daily volume over the past year has been around 937.59 thousand shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Calidi Biotherapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Eric E. Poma, the company employs approximately 28 people and listed since November 01, 2021. Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer.

Technical Performance

CLDI has shown weak momentum, losing -9.81% over the past week and -36.08% over the past quarter, though year-to-date performance is down -13.68%. Short-term trend indicators are bullishly aligned (SMA20 0.02%, SMA50 -18.19%, SMA200 -68.93%). The stock’s 14-day RSI is 44.23 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.59% below its high and over 16.77% above its low. Average 10-day trading volume of 4.34 million shares is significantly above the 3-month average of 810.56 thousand, indicating heightened recent market interest.

Valuation Metrics

Calidi Biotherapeutics, Inc. trades at a P/E ratio of -0.09, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.45 suggesting the stock is closer to book value. The P/FCF stands at -0.08, also below market averages.

Dividend & Fair Value

Calidi Biotherapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.71. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Calidi Biotherapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 31.55%. The prior quarter beat by 3.65%. Over the last six quarters, Apple has recorded several small beats. These include -2.1% in August 13, 2024.

Shareholding & Insider Activity

Calidi Biotherapeutics, Inc. has 5.35 million shares outstanding. The public float is 2.35 million shares, elevated short interest at 8.05% of float. This equals 270.02 thousand shares. The short ratio is 0.32 days. Institutional investors hold 5.58% of the float. Insiders own 20.25%. Leftwich Scott holds 125.00 thousand shares, Camaisa Allan has 76.95 thousand shares and Schoeneck James A has 75.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 850.00 shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Calidi Biotherapeutics has not generated any revenue.
On valuation metrics, Calidi Biotherapeutics trades at a P/E of -0.09, P/S of 0.00 and P/B of 0.45. The current ratio is 1.59 and quick ratio is 1.59. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -263.23 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.52, supported by a cash flow-to-debt ratio of -10.84.

Price Forecast & Outlook

Our AI price prediction model suggests that Calidi Biotherapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -28.42%, with price expected at $0.17 by May 11, 2026, within a range of $0.05 to $0.28 3-Month Outlook: Projected rise of 93.68%, reaching $0.46 by July 24, 2026, with a range of $0.00 to $0.94. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 27, 2027, within a range of $0.00 to $11.22.

Key Takeaways

Calidi Biotherapeutics, Inc. (AMEX:CLDI) shares are down -13.68% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Calidi Biotherapeutics, Inc. trading at a premium to the broader market with a P/E of -0.09. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $1.00, suggesting 321.05% upside. Our AI forecast model points to short-term weakness (-28.42% over two weeks), a medium-term rise (93.68% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Calidi Biotherapeutics, Inc. (CLDI) stock price?

Calidi Biotherapeutics, Inc. (AMEX: CLDI) stock price is $0.24 in the last trading session. During the trading session, CLDI stock reached the peak price of $0.24 while $0.22 was the lowest point it dropped to. The percentage change in CLDI stock occurred in the recent session was 5.09% while the dollar amount for the price change in CLDI stock was $0.01.

CLDI's industry and sector of operation?

The AMEX listed CLDI is part of Biotechnology industry that operates in the broader Healthcare sector. Calidi Biotherapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CLDI?

No Data

How CLDI did perform over past 52-week?

CLDI's closing price is 13.64% higher than its 52-week low of $0.21 where as its distance from 52-week high of $19.20 is -98.76%.

How many employees does CLDI have?

Number of CLDI employees currently stands at 28.

Link for CLDI official website?

Official Website of CLDI is: https://calidibio.com

How do I contact CLDI?

CLDI could be contacted at phone 858 794 9600 and can also be accessed through its website. CLDI operates from 4475 Executive Drive, San Diego, CA 92121, United States.

How many shares of CLDI are traded daily?

CLDI stock volume for the day was 2.73M shares. The average number of CLDI shares traded daily for last 3 months was 937.59K.

What is the market cap of CLDI currently?

The market value of CLDI currently stands at $1.75M with its latest stock price at $0.24 and 7.37M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	28
Beta	1.11
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

CLDI Company Profile and Key Details

Calidi Biotherapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Valuation Metrics

Company Overview

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Key Takeaways

Price Forecast & Outlook